With the exchange offer complete and Medtronic holding no MiniMed shares, the separation is final. Monitor MiniMed's standalone performance as an independent public company (MMED) and any potential impact on Medtronic's diabetes segment revenue. The oversubscription indicates strong shareholder demand for MiniMed exposure.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Oct 14 $94.23entry
- T+1 · 5w ago +1.29%α +1.01% · $95.45
- T+5 · 27d ago −1.27%α −1.73% · $93.03
- T+20 · 6d ago +7.83%α +9.10% · $101.61
- T+23 · todayOpen
- T+60 · in 8w Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Medtronic announced the final results of its exchange offer to spin off its remaining 252,813,348 shares of MiniMed Group (MMED) common stock in exchange for 55,032,401 Medtronic ordinary shares. The offer was oversubscribed with 297,521,390 shares tendered, resulting in a final proration factor of 18.289133%. This completes Medtronic's full divestiture of its MiniMed stake, a significant corporate restructuring event.
Key Facts
- Medtronic exchanged all of its remaining 252,813,348 MiniMed shares for 55,032,401 Medtronic ordinary shares.
- Exchange offer was oversubscribed: 297,521,390 Medtronic shares validly tendered.
- Final proration factor of 18.289133% applied to tendered shares subject to proration.
- Odd-lot shareholders (757,890 shares) not subject to proration.
- Following completion, Medtronic retains no outstanding MiniMed common stock.
- Goldman Sachs and BofA Securities served as dealer managers.
Financial Impact
Medtronic fully divests its MiniMed stake, exchanging 252.8M MiniMed shares for 55.0M Medtronic shares, a net reduction in Medtronic's share count of approximately 55M shares (about 4.1% of outstanding based on ~1.34B shares outstanding). No cash consideration involved.
Risk Factors
- Potential tax implications of the exchange for Medtronic shareholders (filing notes expectation of tax-free treatment but no guarantee).
- MiniMed's ability to succeed as an independent company, any weakness could reflect on Medtronic's prior diabetes strategy.
- No further Medtronic involvement in MiniMed means loss of any upside from MiniMed's future growth.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001628280-26-065819 |
| Document: 0001628280-26-065819-index-headers.html | 0001628280-26-065819 |
| Document: 0001628280-26-065819-index.html | 0001628280-26-065819 |
| Document: 0001628280-26-065819.txt | 0001628280-26-065819 |
Track record
53 reports on MDT
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.30% at T+60 after the Jun 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $101.59 Now $102.88 +1.27% settles Feb 8
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $98.88 Now $102.88 +4.05% settles Feb 1
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $94.63 Now $102.88 +8.72% settles Jan 15
- Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
- Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
- Oct 15, 20264w ago 144 Neutral 3/10 Entry $95.45 Now $102.88 +7.78% settles Jan 12
- Oct 14, 20264w ago SC TO-I/A Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
- Oct 14, 20264w ago 425 Neutral 5/10 Viewing Entry $94.23 Now $102.88 +9.18% settles Jan 11
- Oct 13, 20264w ago SC TO-I/A Neutral 5/10 Entry $93.01 Now $102.88 +10.61% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers